Progyny, Inc. PGNY
36.43 USD +0.48 (+1.34%)
At closeNov 10, 2026, 7:20 PM EST
36.20 -0.23 -0.63%
After hours · Nov 10, 7:20 PM ET
35.00 Day range 36.45
16.30 52-week range 36.43
- YTD
- +41.86%
- 1 year
- +54.23%
News
fool.com Progyny: 3 Key Takeaways for Long-Term Investors Progyny added 1.3 million covered lives for the 2027 plan year. Progyny achieved a near 100% pharmacy attach rate with new clients.
benzinga.com JP Morgan Maintains Neutral on Progyny, Raises Price Target to $35 JP Morgan analyst Lisa Gill maintains Progyny (NASDAQ:PGNY) with a Neutral and raises the price target from $30 to $35.
defenseworld.net Progyny (NASDAQ:PGNY) Reaches New 12-Month High After Earnings Beat Shares of Progyny, Inc. (NASDAQ: PGNY - Get Free Report) reached a new 52-week high during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The company…
benzinga.com Leerink Partners Maintains Outperform on Progyny, Raises Price Target to $38 Leerink Partners analyst Michael Cherny maintains Progyny (NASDAQ:PGNY) with a Outperform and raises the price target from $37 to $38.
benzinga.com Wells Fargo Maintains Overweight on Progyny, Raises Price Target to $38 Wells Fargo analyst Stan Berenshteyn maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $37 to $38.
benzinga.com Citizens Maintains Market Outperform on Progyny, Raises Price Target to $38 Citizens analyst Constantine Davides maintains Progyny (NASDAQ:PGNY) with a Market Outperform and raises the price target from $33 to $38.
benzinga.com Cantor Fitzgerald Maintains Overweight on Progyny, Raises Price Target to $35 Cantor Fitzgerald analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $31 to $35.
marketbeat.com Progyny Q3 Earnings Call Highlights Progyny NASDAQ: PGNY raised the midpoint of its full-year 2026 guidance after reporting record third-quarter revenue and profitability and securing a record 1.3 million new covered lives during its…
seekingalpha.com Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
zacks.com Progyny (PGNY) Tops Q3 Earnings and Revenue Estimates Progyny (PGNY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.45 per share a year ago.
benzinga.com Progyny Q3 2026 Earnings Call Transcript Progyny (NASDAQ:PGNY) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com Progyny Sees Q4 Adj EPS $0.53-$0.58 vs $0.34 Est; Sees Sales $344.700M-$364.700M vs $353.596M Est Progyny (NASDAQ:PGNY) is looking for Q4 Adj EPS of $0.53-$0.58 vs $0.34 analyst estimate. sees sales of $344.700 million-$364.700 million vs $353.596 million analyst estimate.
- benzinga.com Progyny Raises FY2026 Adj EPS Guidance from $2.04-$2.10 to $2.09-$2.13 vs $1.28 Est; Raises FY2026 Sales Guidance from $1.360B-$1.385B to $1.365B-$1.385B vs $1.373B Est Progyny (NASDAQ:PGNY) raises FY2026 Adj EPS guidance from $2.04-$2.10 to $2.09-$2.13 vs $1.28 analyst estimate. Raises FY2026 sales outlook from $1.360 billion-$1.385 billion to $1.365 billion-$1.385…
globenewswire.com Progyny, Inc. Announces Third Quarter 2026 Results Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net IncomeSelling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention…
globenewswire.com New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits Research presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility care Research presented at…
globenewswire.com New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced findings from a new clinical outcomes study…
globenewswire.com Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period…
defenseworld.net Progyny (NASDAQ:PGNY) COO Sells $52,612.00 in Stock Progyny, Inc. (NASDAQ: PGNY - Get Free Report) COO Melissa Cummings sold 1,879 shares of the stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $28.00,…
globenewswire.com Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that it will present new research evaluating…
zacks.com Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock? Progyny (PGNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in…
zacks.com PGNY or CRL: Which Is the Better Value Stock Right Now? Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for…
globenewswire.com Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of…
zacks.com PGNY vs. CRL: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the…
seekingalpha.com Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027 Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026…
zacks.com Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's What You Should Know The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…- benzinga.com Citizens Maintains Market Outperform on Progyny, Raises Price Target to $33 Citizens analyst Constantine Davides maintains Progyny (NASDAQ:PGNY) with a Market Outperform and raises the price target from $31 to $33.
globenewswire.com Progyny, Inc. to Present at the Wells Fargo Healthcare Conference NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark…
defenseworld.net Hsbc Holdings PLC Makes New $760,000 Investment in Progyny, Inc. $PGNY Hsbc Holdings PLC acquired a new stake in shares of Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange…
defenseworld.net 23,600 Shares in Progyny, Inc. $PGNY Bought by Canada Pension Plan Investment Board Canada Pension Plan Investment Board acquired a new stake in Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional…
defenseworld.net Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of “Moderate Buy” from Analysts Shares of Progyny, Inc. (NASDAQ: PGNY - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen analysts that are covering the stock, Marketbeat.com reports. Three…
benzinga.com JP Morgan Maintains Neutral on Progyny, Raises Price Target to $30 JP Morgan analyst Lisa Gill maintains Progyny (NASDAQ:PGNY) with a Neutral and raises the price target from $27 to $30.- benzinga.com Wells Fargo Initiates Coverage On Progyny with Overweight Rating, Announces Price Target of $37 Wells Fargo analyst Stan Berenshteyn initiates coverage on Progyny (NASDAQ:PGNY) with a Overweight rating and announces Price Target of $37.
benzinga.com Truist Securities Maintains Buy on Progyny, Raises Price Target to $36 Truist Securities analyst Jailendra Singh maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $33 to $36.- benzinga.com Barclays Maintains Equal-Weight on Progyny, Lowers Price Target to $30 Barclays analyst Peter Warendorf maintains Progyny (NASDAQ:PGNY) with a Equal-Weight and lowers the price target from $34 to $30.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings…- benzinga.com Progyny Sees Q3 Adj EPS $0.50-$0.52 vs $0.33 Est; Sees Sales $335.000M-$345.000M vs $350.185M Est Progyny (NASDAQ:PGNY) is looking for Q3 Adj EPS of $0.50-$0.52 vs $0.33 analyst estimate. sees sales of $335.000 million-$345.000 million vs $350.185 million analyst estimate.
- benzinga.com Progyny Raises FY2026 Adj EPS Guidance from $1.98-$2.09 to $2.04-$2.10 vs $1.29 Est; Lowers FY2026 Sales Guidance from $1.365B-$1.405B to $1.360B-$1.385B vs $1.384B Est Progyny (NASDAQ:PGNY) raises FY2026 Adj EPS guidance from $1.98-$2.09 to $2.04-$2.10 vs $1.29 analyst estimate. Lowers FY2026 sales outlook from $1.365 billion-$1.405 billion to $1.360 billion-$1.385…
benzinga.com Progyny Q2 Adj. EPS $0.55 Beats $0.34 Estimate, Sales $350.511M Beat $348.682M Estimate Progyny (NASDAQ:PGNY) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.34 by 61.76 percent. This is a 14.58 percent increase over earnings of $0.48 per…
benzinga.com This Clorox Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Wall Street analysts change outlook on top stocks. See upgrade, downgrade, and initiation changes on our analyst ratings page. CLX stock has mixed reviews.
benzinga.com Barclays Downgrades Progyny to Equal-Weight, Raises Price Target to $34 Barclays analyst Peter Warendorf downgrades Progyny (NASDAQ:PGNY) from Overweight to Equal-Weight and raises the price target from $27 to $34.- benzinga.com BTIG Maintains Buy on Progyny, Raises Price Target to $40 BTIG analyst David Larsen maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $30 to $40.
- benzinga.com Canaccord Genuity Maintains Buy on Progyny, Raises Price Target to $36 Canaccord Genuity analyst Richard Close maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $30 to $36.
benzinga.com Top 3 Health Care Stocks That May Implode This Month Warning: RSI is above 70 for 3 overbought stocks in healthcare. Progyny, 10X Genomics, and Privia Health have high RSI values and strong price action.- benzinga.com Keybanc Maintains Overweight on Progyny, Raises Price Target to $35 Keybanc analyst Scott Schoenhaus maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $30 to $35.
- benzinga.com Truist Securities Maintains Buy on Progyny, Raises Price Target to $33 Truist Securities analyst Jailendra Singh maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $30 to $33.
- benzinga.com B of A Securities Maintains Buy on Progyny, Raises Price Target to $31 B of A Securities analyst Michael Cherny maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $29 to $31.
benzinga.com This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. See what other analysts think of these stocks.- benzinga.com Canaccord Genuity Upgrades Progyny to Buy, Raises Price Target to $30 Canaccord Genuity analyst Richard Close upgrades Progyny (NASDAQ:PGNY) from Hold to Buy and raises the price target from $19 to $30.
- benzinga.com Barclays Maintains Overweight on Progyny, Raises Price Target to $27 Barclays analyst Glen Santangelo maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $23 to $27.